Top Markets
#1 Resolv wstUSR Resolv wstUSR +114.61%
#2 Luxxcoin Luxxcoin +45.15%
#3 ResearchCoin ResearchCoin +21.62%
#4 Reactive Network Reactive Network +21.45%
#5 Layer3 Layer3 +19.67%
#6 Orderly Network Orderly Network +16.55%
#7 Aria.AI Aria.AI +12.61%
#8 Bitgert Bitgert +11.76%
#9 Lisk Bridged wstETH (Lisk) Lisk Bridged wstETH (Lisk) +9.32%
#10 KAITO KAITO +9.04%
Coin of the day
Resolv wstUSR Resolv wstUSR
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
CSL Limited CSL Limited

CSL Limited

CSL
Rang in Aktien #432
CSL Limited researches, develops, manufactures, markets, and distributes... CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Aktienkurs
$99.32
Marktkapitalisierung
$48.20B
Veränderung (1 Tag)
0.98%
Veränderung (1 Jahr)
-32.14%
Land
AU
Handel CSL Limited (CSL)

Kategorie

Healthcare
P/S-Verhältnis für CSL Limited (CSL)
P/S-Verhältnis zum April 2026 TTM: 3.04
Laut den neuesten Finanzberichten und dem Aktienkurs von CSL Limited beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 3.04. Am Ende des Jahres 2024 lag das P/S-Verhältnis bei 6.41.
P/S-Verlauf für CSL Limited von 2000 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
2026 (TTM) 3.04 -38.45%
2025 4.94 -22.88%
2024 6.41 -5.17%
2023 6.76 -18.55%
2022 8.30 -11.89%
2021 9.41 -32.01%
2020 13.85 68.62%
2019 8.21 -5.05%
2018 8.65 -3.44%
2017 8.96 40.54%
2016 6.37 10.70%
2015 5.76 -10.38%
2014 6.42 5.17%
2013 6.11 32.22%
2012 4.62 7.93%
2011 4.28 4.43%
2010 4.10 -0.89%
2009 4.14 -28.34%
2008 5.77 13.98%
2007 5.06 47.22%
2006 3.44 43.15%
2005 2.40 -30.03%
2004 3.43 131.43%
2003 1.48 -77.36%
2002 6.55 -22.18%
2001 8.42 0.00%
2000 0.00 0.00%
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
3.32 9.17%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.42 209.87%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
5.60 84.08%
US
UCB SA UCB SA
UCB SA
UCB.BR
6.36 109.07%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
13.15 332.61%
NL